NCT01328106View on ClinicalTrials.gov

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

November 30, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

May 31, 2012

Conditions

GNA11 Mutation-positive Metastatic MelanomaGNAQ Mutation-positive Metastatic MelanomaCancerMetastatic Uveal Melanoma

Interventions

DRUG

GSK1120212

Repeating oral dose

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY